Between the rarity of a securities fraud case going to trial, attorneys dropping at the last minute and investors alleging they were defrauded of millions, the April bench trial against the former CEO of a pharmaceutical packaging company would have been noteworthy in any year.

But with the case the first to go before a Delaware federal court in person since the pandemic began and the parties having just a few weeks between the trial being confirmed and opening statements, Cozen O’Connor attorneys are considering U.S. District Judge Richard G. Andrews’ awarding of both investment losses and punitive damages this week an especially significant win.